The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Open accessAbstract
The medical history of cancer began millennia ago. Historical findings of patients with cancer date back to ancient Egyptian and Greek civilizations, where this disease was predominantly treated with radical surgery and cautery that were often ineffective, leading to the death of patients. Over the centuries, important discoveries allowed to identify the biological and pathological features of tumors, without however contributing to the development of effective therapeutic approaches until the end of the 1800s, when the discovery of X-rays and their use for the treatment of tumors provided the first modern therapeutic approach in medical oncology. However, a real breakthrough took place after the Second World War, with the discovery of cytotoxic antitumor drugs and the birth of chemotherapy for the treatment of various hematological and solid tumors. Starting from this epochal turning point, there has been an exponential growth of studies concerning the use of new drugs for cancer treatment. The second fundamental breakthrough in the field of oncology and pharmacology took place at the beginning of the '80s, thanks to molecular and cellular biology studies that allowed the development of specific drugs for some molecular targets involved in neoplastic processes, giving rise to targeted therapy. Both chemotherapy and target therapy have significantly improved the survival and quality of life of cancer patients inducing sometimes complete tumor remission. Subsequently, at the turn of the third millennium, thanks to genetic engineering studies, there was a further advancement of clinical oncology and pharmacology with the introduction of monoclonal antibodies and immune checkpoint inhibitors for the treatment of advanced or metastatic tumors, for which no effective treatment was available before. Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment. Currently, several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, we will certainly assist to a new revolution in the field of medical oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
McCubrey, J. A., Abrams, S. L., Stadelman, K. M., Chappell, W. H., LaHair, M. M., Ferland, R. A., & Steelman, L. S. (2009) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2009.10.016 · Cited by 44
Ramos-Esquivel, A., Laat, A. V. D., Rojas-Vigott, R., Juárez, M., & Corrales, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000236 · Cited by 43
Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases
Wissing, M. D., van Leeuwen, F. W. B., van der Pluijm, G., & Gelderblom, H. A. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1896 · Cited by 42
A dinosaurian facial deformity and the first occurrence of ameloblastoma in the fossil record
Dumbravă, M. D., Rothschild, B. M., Weishampel, D. B., Csiki‐Sava, Z., Andrei, R., Acheson, K. A., & CODREA, V. A. (2016) · Scientific Reports · doi:10.1038/srep29271 · Cited by 42
Cao, L., Liu, H., Yue, Z., et al. (2018) · BioMetals · doi:10.1007/s10534-018-0123-5 · Cited by 42
IRON, INFLAMMATION AND INVASION OF CANCER CELLS
Fischer‐Fodor, E., Miklášová, N., Berindan‐Neagoe, I., & Saha, B. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-492 · Cited by 41
Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu, H. J., Jain, R. K., & Baxter, L. T. (1998) · PubMed · Cited by 41
The contribution of Marie Skłodowska-Curie to the development of modern oncology
Kułakowski, A. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4712-1 · Cited by 40
Lange, A., Prenzler, A., Frank, M., Golpon, H., Welte, T., & von der Schulenburg, J.-M. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-192 · Cited by 38
Sunitinib in the Treatment of Advanced Solid Tumors
Imbulgoda, A., Heng, D. Y. C., & Kollmannsberger, C. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_9 · Cited by 38
Poulin-Costello, M., Azoulay, L., Cutsem, E. V., Peeters, M., Siena, S., & Wolf, M. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0271-z · Cited by 37
Monoclonal antibodies in cancer therapy
Guo, Y., Hou, Q.-Y., & Wang, N. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0583-7 · Cited by 35
Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma
Sudbrock, F., Schmidt, M. C., Simon, T., Eschner, W., Berthold, F., & Schicha, H. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1391-7 · Cited by 30
Beginning the CAR T cell therapy revolution in the US and EU
Grupp, S. A. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.004 · Cited by 29
Steins, M. B., Thomas, M., & Geißler, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_1 · Cited by 28
Liberal, F. D. C. G., Tavares, A., & Tavares, J. M. R. S. (2014) · Medical Physics · doi:10.1118/1.4897240 · Cited by 26
Therapeutic applications of chemical warfare agents.
GILMAN, A. (1946) · PubMed · Cited by 25
Müller, V., Clemens, M., Jassem, J., Al-Sakaff, N. J. A., Auclair, P., Nüesch, E., Holloway, D., Shing, M., & Bang, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4183-2 · Cited by 25
Assessing Progress in Reducing the Burden of Cancer Mortality, 1985-2005
Soneji, S. S., Beltrán‐Sánchez, H., & Sox, H. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8952 · Cited by 23
Radiation fractionation: the search for isoeffect relationships and mechanisms
Moulder, J. E., & Seymour, C. B. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1376764 · Cited by 23
Oncophage: step to the future for vaccine therapy in melanoma
di Pietro, A., Tosti, G., Ferrucci, P. F., & Testori, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802517970 · Cited by 21
Rossi, A., Maione, P., & Gridelli, C. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1051 · Cited by 20
Daunomycin Treatment in Chronic Lymphoproliferative Disorders
Bonadonna, G., Monfardini, S., & Guindani, A. (1968) · Tumori Journal · doi:10.1177/030089166805400605 · Cited by 17
Cheng, Y., Kiess, A. P., Herman, J. M., Pomper, M. G., Meltzer, S. J., & Abraham, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128152 · Cited by 15
Amdahl, J., Chen, L., & Delea, T. E. (2016) · Oncology and Therapy · doi:10.1007/s40487-016-0030-2 · Cited by 11
Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells
Badieyan, Z. S., & Hoseini, S. S. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-018-0507-9 · Cited by 10
Sanchez, G. M., & Meltzer, E. S. (2012) · Lockwood Press eBooks · doi:10.5913/2012017 · Cited by 10
Goldschmidt, H., Moreau, P., Ludwig, H., Niesvizky, R., Chng, W. J., Joshua, D., Weisel, K. C., Spencer, A. G., Orlowski, R. Z., Feng, S., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1376743 · Cited by 7
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
Sex disparities matter in cancer development and therapy
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B., & Haupt, Y. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00348-y · Cited by 331
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities
Shemesh, C. S., Hsu, J. C., Hosseini, I., Shen, B.-Q., Rotte, A., Twomey, P., Girish, S., & Wu, B. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.038 · Cited by 286
Metadata
- Authors
- Falzone, L., Salomone, S., & Libra, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-13
- Volume
- 9
- Pages
- 1300-1300
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2900960361
- Cited by
- 908
- References
- 228
- FWCI
- 50.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.